Le Lézard
Classified in: Health
Subject: PDT

Breakthrough in Medical Electronics - A Novel Mixed & Augmented Reality Smart Glasses Surgical Navigation Solution

TAICHUNG, Dec. 10, 2019 /PRNewswire/ -- The mixed reality technology for surgery usually shown in the movies has now become a reality with the latest technological offering from the Taiwan-based company ? Taiwan Main Orthopaedics Biotechnology and the branding name of medical devices is SURGLASSES. They are ready to announce a new device, which is called Caduceus, to the spinal navigation market. The core technologies are used to position particular entry points and they can reveal the necessary angles for the screws to be fixed in for a spinal surgery.

Breakthrough in Medical Electronics ? A Novel Mixed & Augmented Reality Smart Glasses Surgical Navigation Solution

These new glasses allow surgeons a superiority rivaling any fictional character, especially the man with the X-ray eyes. Combining mixed reality technology with surgical navigation, these smart surgical glasses will allow surgeons to see through a patient's body and visualize a 3D model of the anatomy of the patient's vascular and nervous systems. The device uses the trajectory of a surgical instrument like a GPS system. Caduceus smart surgical glasses are designed to augment the skills of a surgeon during complicated procedures. Traditionally, a surgeon uses fluoroscopy to verify the needle insertion, requiring them to periodically look away from the patient to observe the monitor. Now with Caduceus smart surgical glasses, surgeons are able to see the exact position of the needle without ever taking their eyes off of the patient. The patient benefits from the innovation of the Caduceus smart surgical glasses because recovery times are much quicker due to smaller incisions during the procedure.

Caduceus spinal navigation will not only reduce the exposure of the doctors and surgeons to radiation but also reduce the surgery time and increase the efficiency of the surgeons while performing minimal invasive surgeries with accuracy up to 1.5mm. They recently performed the non-clinical testing of their product at Miami Anatomical Research Center where a local surgeon in Miami has first tried the system with major brands instrumentation hardware. It tested the product over the SAWBONES dummy for Spine Surgery. As per the observation of the spinal surgeon, the Caduceus is the new breakthrough in the medical electronics which can bring the efficiency of the surgeons to a high-tech level.

Caduceus is the smart glasses with mixed reality and high precision surgical navigation functions that allow surgeons to see through a patient's body. It has a very powerful surgical guidance system and will become the standard in the near future. Caduceus is going through the final process of FDA approval and will be in full fledge production mid next year. During the testing of the Caduceus over the SAWBONES dummies, a total of 60 screws from 5 different companies were used and were successfully tested. The accuracy of instrumentation was 97%.

Taiwan Main Orthopaedics Biotechnology: www.surglasses.com

SOURCE Taiwan Main Orthopaedics Biotechnology

These press releases may also interest you

at 05:00
July 6, 2020 Amsterdam, the Netherlands ? Royal Philips today announced that the exchange ratio for the dividend for the year 2019 has been determined. The exchange ratio is 1 new common share for every 49.2971 existing common shares. This...

at 04:50
Global eubiotics market revenue is expected to reach over USD 6.8 billion by 2026, as reported in the latest study by Global Market Insights, Inc. High effectiveness of eubiotics supplementation in improving the feed conversion ratio, enhancing...

at 04:35
The global prescription lens market size is expected to reach USD 51.4 billion by 2027, expanding at a CAGR of 4.5%, according to a report conducted by Grand View Research, Inc. Uncorrected refractive error cases are majorly contributing in the...

at 04:09
We are advised by Sino Medical Sciences Technology Inc. (SINOMED) that journalists and other readers should disregard the news release, SINOMED® Completes Last Patient Follow-Up of the PIONEER-III Pivotal US and Japanese Trial of the BuMA Supreme®...

at 04:05
Mission Therapeutics ("Mission"), a drug discovery and development company focused on selectively inhibiting deubiquitylating enzymes (DUBs), today announced that it has raised $15m (£12m) in equity investment. The round was led by existing investor...

at 04:00
HOYA Corporation (TSE:7741, "HOYA") and Hitachi, Ltd. (TSE:6501, "Hitachi") today announced a five year contract regarding Endoscopic Ultrasound Systems [EUS] by which, i) the parties will strengthen technical collaboration, and ii) Hitachi will...

News published on 10 december 2019 at 03:34 and distributed by: